144 related articles for article (PubMed ID: 2967195)
1. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Matta WH; Stabile I; Shaw RW; Campbell S
Fertil Steril; 1988 Jun; 49(6):1083-5. PubMed ID: 2967195
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
4. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri].
Yoshioka N
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1255-60. PubMed ID: 8543851
[TBL] [Abstract][Full Text] [Related]
6. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog.
Chia CC; Huang SC; Chen SS; Kang JY; Lin JC; Lin YS; Huang KF; Lee HJ; Zheng CC
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):124-8. PubMed ID: 17197352
[TBL] [Abstract][Full Text] [Related]
8. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
9. Blood flow changes in the uterus induced by treatment with GnRH analogues.
Shaw RW
Hum Reprod; 1996 Nov; 11 Suppl 3():27-32. PubMed ID: 9147099
[No Abstract] [Full Text] [Related]
10. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
11. The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography.
Aleem FA; Predanic M
Gynecol Endocrinol; 1995 Sep; 9(3):253-8. PubMed ID: 8540296
[TBL] [Abstract][Full Text] [Related]
12. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
Donnez J; Schrurs B; Gillerot S; Sandow J; Clerckx F
Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
[TBL] [Abstract][Full Text] [Related]
13. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
[TBL] [Abstract][Full Text] [Related]
14. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists.
Adamson GD
Am J Obstet Gynecol; 1992 Feb; 166(2):746-51. PubMed ID: 1531577
[TBL] [Abstract][Full Text] [Related]
15. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma diagnosed during treatment with agonist of luteinizing hormone-releasing hormone for presumed uterine fibroid.
Loong EP; Wong FW
Fertil Steril; 1990 Sep; 54(3):530-1. PubMed ID: 2118862
[TBL] [Abstract][Full Text] [Related]
17. Infarcted intramural uterine leiomyomata during buserelin acetate treatment.
Chang MY; Tsai FB; Soong YK
Changgeng Yi Xue Za Zhi; 1993 Jun; 16(2):129-32. PubMed ID: 8339156
[TBL] [Abstract][Full Text] [Related]
18. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density.
Bianchi G; Costantini S; Anserini P; Rovetta G; Monteforte P; Menada MV; Fagà L; De Cecco L
Maturitas; 1989 Sep; 11(3):179-85. PubMed ID: 2512467
[TBL] [Abstract][Full Text] [Related]
19. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
[TBL] [Abstract][Full Text] [Related]
20. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
